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Human gliomaint function in the regulation of processes often altered in cancer. Although
increased expression of caveolin-1 seems to be the norm in the glioma family of malignancies, populations of
caveolin-1 positive and negative cells coexist among glioblastoma specimens. As no data are available to date
on the contribution of such cells to the phenotype of glioblastoma, we manipulated caveolin-1 in the
glioblastoma cell line U87MG. We showed that caveolin-1 plays a critical role in the aggressiveness of
glioblastoma.We identiﬁed integrins as themain set of genes affected by caveolin-1.We reported here that the
phenotypic changes observed after caveolin-1modulationweremediated byα5β1 integrins. As a consequence
of the regulation of α5β1 levels by caveolin-1, the sensitivity of cells to the speciﬁc α5β1 integrin antagonist,
SJ749,was affected.Mediator of caveolin-1 effects,α5β1 integrin, is also amarker for glioma aggressiveness and
an efﬁcient target for the treatment of glioma especially the ones exerting the highest aggressive phenotype.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionCaveolin-1 is a scaffolding protein that directly interacts with
several signaling molecules (growth factor receptors, kinases, G-
proteins and adhesion molecules) in caveolae to control their
subcellular distribution and activation status [1–3]. Additionally,
caveolin-1 was described as a direct or indirect regulator of genes
involved in tumor development and progression (IGFR [4], BRCA1 [5],
ERα [6], cyclin D1 [7] and survivin [8]). Such checkpoint functions
confer to caveolin-1 a crucial role in the regulation of proliferation,
differentiation, apoptosis, adhesion and invasion. It is therefore not
surprising that sporadic mutations or altered expression of caveolin-1
are often observed during cell transformation, invasion and metas-
tasis. Despite signiﬁcant studies done over the last ten years showing
the role of caveolin-1 in malignancy, its function remains complex and
controversial. Caveolin-1 was described either as a tumor suppressor
or as a tumor promoter given its levels in tumors versus non
neoplastic tissues [9,10]. Such contradictions tend to be explained by
the fact that the expression of caveolin-1 undergoes dynamic changes
during tumor progression. Downregulated during cell transformation
by oncogenes or environmental carcinogens to allow proliferation,nmemory of Dr Klotz deceased
ut Gilbert Laustriat, CNRS UMR
67400 Illkirch, France. Tel.:
(S. Martin).
l rights reserved.caveolin-1 happens to be overexpressed in malignant and metastatic
tumors to promote survival and multidrug resistance [9]. Such
biphasic expression pattern of caveolin-1 seems therefore intimately
linked to the protein function.
Glioblastoma is the most common intrinsic brain tumor in adults
and is nearly uniformly fatal. Despite advances in neuroimaging,
neurosurgery, radiation and medical oncology, the prognosis for
patient with glioblastoma did not improve in the last 30 years with a
median survival of 9–15months [11]. Although increased expression of
caveolin-1 seems to be a norm in the glioma family of malignancies
(http://cgap.nci.nih.gov) [12–17], Cassoni et al. recently showed that
caveolin-1 immunoreactivity is variably displayed among glioma. In
half of the glioblastoma specimens studied, only 25–75% of neoplastic
cells stained positive for caveolin-1 [17] suggesting that populations of
caveolin-1 positive and negative cells coexist among glioblastoma
specimens. No data are available to date on the contribution of such
cells to the phenotype of glioblastoma. Therefore, we manipulated the
levels of caveolin-1 in a glioblastoma cell line (U87MG) and showed
that its reduction shifted cells towards an evenmore aggressive pheno-
type as conversely the forced expression of caveolin-1 slowed down
proliferation, clonogenicity and invasion. Using PCR array strategies, we
showed thatonly 20%of the genes studiedwere signiﬁcantly affectedby
caveolin-1. Half of them belonged to the integrin family and their
expression was always inversely correlated to caveolin-1. We showed
that α5β1 integrin mediates the phenotypic alterations observed after
caveolin-1 manipulation. Finally, as a consequence of the regulation of
α5β1 levels by caveolin-1, the sensitivity of cells to the speciﬁc α5β1
integrin antagonist, SJ749, was modulated.
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2.1. Cell lines, culture conditions and transfection
A172 and U87MG cell lines (ATCC) were cultured in EMEM
supplemented with 10% heat-inactivated FCS and 0.6 mg/ml glutamine
(Biowittaker).When indicated, transfectionsof theplasmids constructs or
siRNAwere performed using Lipofectamine 2000 reagent (Invitrogen) or
Arrest-In™ (OpenBiosystems) following the manufacturer's instructions.
2.2. Chemicals
SJ749 ((S)-2-[(2,4,6-trimethylphenyl) sulfonyl] amino-3-[7-benzy-
loxycarbo nyl-8-(2-pyridi nylaminomethyl)-1-oxa-2,7-diazaspiro-
(4,4)-non-2-en-3-yl] carbonylamino] propionic acid) was synthesized
as described in the patent WO 97/33887. U0126 was obtained by Cell
Signaling and used at the concentration of 10 μM for 24 h.
2.3. Small interfering RNA and plasmids
Non silencing siRNA (siRNAcontrol), caveolin-1-targeting siRNA
(siRNAcav-1), α2 integrin subunit-targeting siRNA (siRNAα2) and α5
integrin subunit-targeting siRNA (siRNAα5) were obtained from
Dharmacon Research and transfected at 100 nM for 72 h as recom-Fig. 1. Caveolin-1 modulates growth, clonogenicity and transmigration. (A) Expression of cav
transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pEGFPcontrol or p
mRNA (caveolin-1) was determined by qPCR in U87MG transfected transiently with siRNAcon
represent the percentage of increase or decrease of CAV1mRNA in siRNAcav-1- and pEGFPcav-1
with the reporter gene, cyclophilin. (C) Proliferation of U87MG transfected transiently with s
determined at 72 h using the MTS assay. Histograms represent the percentage of proliferation
and pEGFPcontrol). (D) Clonogenicity of U87MG transfected transiently with siRNAcontrol or siR
the clonogenic assay. Histograms represent the percentage of residual clones formed by siR
pEGFPcontrol) after 72 h growth in 2%-FCS medium and 6 days regrowth. Plating efﬁciency
pEGFPcav-1 respectively. (E) Transmigration of U87MG transfected transiently with siRNA
determined using ﬁbronectin (FN)-coated Transwell. Histograms represent the percentage
respective control (i.e. siRNAcontrol and pEGFP) after 24 h. Data are represented as mean (n=mended. Non silencing shRNA (shRNAcontrol), caveolin-1-targeting
shRNA (shRNAcav-1) and α5-targeting shRNA (shRNAα5) already
subcloned into the pSHAG-MAGICS2 (pSM2) plasmid were obtained
from OpenBiosystems. EGFP-tagged caveolin-1 (pEGFPcav-1) construct
was created by introducingHindIII andBamHI restriction sites in 5′ and
3′ of the caveolin-1 CDSbyPCRand by subcloning the resultingHindIII/
cav-1/BamHI fragment into a pEGFP-N3control expression vector (BD
Biosciences Clontech). pcDNAα5 was obtained by subcloning the
human α5 cDNA of the pECEα5 integrin plasmid (provided by Dr. E.
Ruoslahti, The Burnham Institute, La Jolla, CA) in the XbaI/NotI sites of
the expression vector pcDNA3.1 (Invitrogen). Stable cell lines were
obtained after transfection of 1 μg of each plasmid and selection with
adequate antibiotics. Expression and functionality of the constructs
were conﬁrmed by western blot, qPCR and/or confocal microscopy.
2.4. Real-time quantitative PCR
RNAwas extracted using Trizol andwas transcribed into cDNA using
high capacity cDNAkit (Applied Biosystems). Real-time quantitative PCR
was performed using the ABI7000 SYBRGreen PCR detector with the
following probes: cyclophilin forward 5′-CAGGTCCTGGCATCTTGTCC-3′
and reverse 5′-TTGCTGGTCTTGCCATTCCT-3′; ITGA5 forward 5′-
GGGCAGCAGGACAGGGTTAC-3′ and reverse 5′-GCCTTGCCAGAAATAGC
TTCC-3′; ITGB1 forward 5′-CAAATTGTGGGTGGTGCACA-3′ and reverseeolin-1 (cav-1) and GAPDH was determined by western blot (WB) in U87MG transfected
EGFPcav-1. Western blots are representative of 3–5 independent experiments. (B) CAV1
trol or siRNAcav-1 (100 nM for 72 h) or stably with pEGFPcontrol or pEGFPcav-1. Histograms
-transfected cells versus respective control (i.e. siRNAcontrol and pEGFPcontrol) normalized
iRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pEGFPcontrol or pEGFPcav-1 was
of siRNAcav-1- and pEGFPcav-1-transfected cells versus respective control (i.e. siRNAcontrol
NAcav-1 (100 nM for 72 h) or stably with pEGFPcontrol or pEGFPcav-1 was determined using
NAcav-1- and pEGFPcav-1-transfected cells versus respective control (i.e. siRNAcontrol and
is 0.5±0.2, 0.8±0.3, 0.5±0.1 and 0.3±0.1 for siRNAcontrol, siRNAcav-1, pEGFPcontrol and
control or siRNAcav-1 (100 nM for 72 h) or stably with pEGFPcontrol or pEGFPcav-1 was
of siRNAcav-1- and pEGFPcav-1-transfected cells which transmigrated through FN versus
3–5)±SEM (⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001).
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GAGTCTTTCA-3′ and reverse 5′-GTTCACCTCGATCTTCACTTTCTG-3′;
CAV1 forward 5′-ACCGCGACCCTAAACACCTC-3′ and reverse 5′-
CCTTCCAAATGCCGTCAAAA-3′ (Invitrogen). Relative levels of mRNA
gene expression were calculated using the 2−ΔΔCt method [18].
2.5. PCR array
PCR array were performed according to the manufacturer's protocol
(SuperArray). Brieﬂy, 1 μg cDNA (obtained from RNA using the RT2 PCRFig. 2. Transcriptome analysis of siRNAcontrol-, siRNAcav-1-, pEGFPcontrol- or pEGFPcav-1-transfec
DNA damage, (B) apoptosis/cell senescence, (C) signal transduction/transcription, (D) angiog
U87MG transfected transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with
of each gene mRNA in siRNAcav-1- and pEGFPcav-1-transfected cells versus respective control
RPL13A, G3PD/GAPD, b-ACTIN. Columns, means of 3 independent experiments; bars, SEM wArray First StrandKit (SuperArray))wasmixedwitha ready touseRT2Real-
TimeSYBRGreenPCRmastermix (SuperArray) andaliquoted intoa96-well
plate containing pre-dispensed gene-speciﬁc primer sets (RT2 Proﬁler™
PCRArray,HumanCancerPathwayFinder™).Real-TimePCRwasperformed
according to manufacturer's protocol and analyzed as described above.
2.6. Western blot
Cells were lysed 30min on ice in ice-cold lysis buffer (1% Triton-X100,
NaF 100 mM, NaPPi 10 mM, Na3VO4 1 mM in PBS, supplemented withted U87MG using PCR arrays. mRNA of genes involved in the regulation of (A) cell cycle/
enesis, (E) invasion/metastasis and (F) adhesion was determined by PCR array (qPCR) in
pEGFPcontrol or pEGFPcav-1. Histograms represent the percentage of increase or decrease
(i.e. siRNAcontrol and pEGFPcontrol) normalized to the reporter genes, B2M, HGPRT/HPRT,
ith ⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001.
Fig. 2 (continued).
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were prepared from FCS-free conditioned media. Protein (10 μg) was
separated by SDS-PAGE (BioRad) and transferred to PVDF membranes
(Amersham). For phosphorylation detection, cells were directly lysed in
Laemmli buffer (BioRad) supplemented by β-mercaptoethanol (1:20).
Blotswere probedwith anti-α1 (1:200, R-164, Santa Cruz Biotchnologies),
anti-α2 (1:200,N-19, SantaCruzBiotchnologies), anti-α3 (1:1000,AB1920,
Chemicon), anti-αV (1:3000, AB1930, Chemicon), anti-α5 (1:4000,
AB1928, Chemicon), anti-β1 (1:1000, 9EG7, gift from Dr. Vestweber),
anti-GFP (1:3000, Roche), anti-caveolin-1 (1:1000, N-20, Santa CruzBiotchnologies), anti-PAI-1 (1:1000, H-135, Santa Cruz Biotchnologies),
phospho-MAPK family antibodies and MAPK family antibodies (Sampler
kit #9910 and #9926, Cell Signaling) and anti-GAPDH (1:50000, MAB374,
Chemicon) followed by the HRP-conjugated antibodies (1:10000, Pro-
mega). The proteins were visualized with enhanced chemiluminescence.
2.7. Flow cytometry
Cells (2×105) were incubated 30 min at room temperature with
10 μg/ml anti-α5 (MAB11, gift from Dr. Humphries, King's College,
Fig. 3. Caveolin-1 regulates PAI-1 expression. (A) SERPINE1 (PAI-1)mRNAwas determined
by qPCR in U87MG transfected stably with shRNAcontrol, shRNAcav-1, pEGFPcontrol or
pEGFPcav-1. Histograms represent the percentage of increase or decrease of SERPINE1
mRNA in shRNAcav-1- and pEGFPcav-1-transfected cells versus respective control (i.e.
shRNAcontrol and pEGFPcontrol) normalized with the reporter gene, cyclophilin. (B)
Expression of PAI-1 was determined by western blot (WB) in the supernatant of U87MG
transfected stably with shRNAcontrol, shRNAcav-1, pEGFPcontrol or pEGFPcav-1. Western blots
are representative of 3–5 independent experiments. Histograms show the percentage of
PAI-1 protein expression determined by densitometry analysis in shRNAcav-1- and
pEGFPcav-1-transfected cells versus respective control (i.e. shRNAcontrol and pEGFPcontrol).
Data are represented as mean (n=3–5)±SEM (⁎Pb0.05).
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Georges-Labouesse, IGBMC, Strasbourg, France) in PBS/0.1% azide/1%
FBS. After washing, cells were incubated with the indicated ALEXA488-
or PE-labeled secondary antibody (Molecular Probes, 1:100) 30 min in
the dark at room temperature. After washing, cells were resuspended
in 500 μl PBS/0.1% azide/1% FCS. Surface expressions of integrins were
measured with a FACS Calibur (Becton Dickinson, Flow cytometry
facility, IGBMC, Strasbourg).
2.8. Adhesion assay
Cells (2×105/well, 96 well plate) were plated on poly-L-lysine
(PL, 100 μg/ml, Sigma), ﬁbronectin (FN, 10 μg/ml, Calbiochem) or
collagen type I (COL, 10 μg/ml, Sigma)-coated 96 well plates for 1 h.
Adhesion was measured after coloration with 0.1% crystal violet by
absorbance reading at 595 nm and expressed as a percentage of
adhesion versus control on poly-L-lysine.
2.9. Proliferation assay
Cells (1×103/well, 96 well plate) were plated on plastic and cell
viability was determined after 72 h by CellTiter96 Aqueous One
Solution Cell Proliferation Assay (Promega) according to manufac-
turer's instruction.
2.10. Transmigration assay
Transwell polycarbonate membrane inserts (24 well, 8 μm pores,
Corning) were coated 1 h at room temperature under laminar ﬂow
with 10 μg/ml ﬁbronectin. The lower compartments were ﬁlled with
10% FCS culture medium and 2×105 cells were seeded onto the ﬁlters
in 0% FCS culture medium containing either solvent (50% H2O/50%
methanol) or 10 μM SJ749 for 24 h. Cells that had transmigrated and
adhered to the lower surface were ﬁxed in 4% paraformaldehyde for
10 min and stained with 0.1% crystal violet and counted. No cells were
detected in the lower chamber.
2.11. Clonogenic assay
After attachment (250 cells/well, 6 well plate), cells were left
untreated or treated with solvent (50% H2O/50% methanol) or SJ749
(10 and 30 μM) for 72 h in 2%-FCS containing medium. Medium was
refreshed and cells were allowed to regrow in fresh 10%-FCS
containing medium for 6 days. Clonogenic survival was determined
by counting residual clones stained with 0.1% crystal violet. Results
were expressed either as the percentage of clones versus control or
when performed in the presence of SJ749 as surviving fraction. The
surviving fraction was determined as: SF=PE of experimental group/
PE of control group. The plating efﬁciency was determined as:
PE=number of surviving cells/number of cells plated. PE are indicated
for each cell line in the ﬁgure legend.
2.12. Statistical analysis
Data are represented as mean±SEM. In all cases, n refers to the
number of independent experiments. Statistical analyses were donewith
the Student's t-test andANOVAwherePb0.05was considered signiﬁcant.
3. Results
3.1. Caveolin-1 modulates growth, clonogenicity and transmigration
To directly assess the role of caveolin-1 in human glioblastoma, we
modulated its expression in the human glioblastoma cell line U87MG.
Depletion (in siRNAcav-1- versus siRNAcontrol-transfected cells) and
overexpression (in pEGFPcav-1- versus pEGFPcontrol-transfectedcells) of caveolin-1 were detected at the protein and mRNA level
(Fig. 1A, B). Abrogation or forced expression of caveolin-1 in U87MG
signiﬁcantly inﬂuenced U87MG phenotype. Downregulation of
caveolin-1 increases proliferation, clonogenicity and transmigration
(53±19%, 65±8% and 75±3% increase respectively in siRNAcav-1
versus siRNAcontrol, Fig. 1C–E). Opposite effects were observed when
caveolin-1 was overexpressed as proliferation, clonogenicity and
transmigration was reduced (47±8%, 42±8% and 67±7% reduction
respectively in pEGFPcav-1 versus pEGFPcontrol, Fig. 1C–E). Data suggest
that caveolin-1 expression correlates with glioma aggressiveness.
3.2. Caveolin-1 regulates genes involved in cell invasion, metastasis and
adhesion especially integrins
PCR arrays (Human Cancer Pathways) were undertaken to clarify
how caveolin-1 affects U87MGphenotype. Among the genes screened,
only 20% were signiﬁcantly affected by the modulation of caveolin-1
(Fig. 2). Twomajor classes of genes were modulated by caveolin-1. The
ﬁrst one includes genes involved in the regulation of cell invasion and
metastasis (6%, MMP1, MMP2, SERPINE1, SERPINB5 and TWIST,
Fig. 2E). To validate PCR array data obtained for this group of genes,
we selected SERPINE1 (PAI-1). PAI-1 is a serine protease inhibitor
involved in extracellular matrix turnover and regulation of glioma cell
motility and invasion. qPCR and western blot analysis of PAI-1 showed
that PAI-1 was inversely correlated to caveolin-1 expression. Down-
regulation of caveolin-1 up regulates PAI-1 both at the mRNA and
protein level (275±35% and 350±100% increase of PAI-1 mRNA and
protein respectively in shRNAcav-1 versus shRNAcontrol, Fig. 3A, B).
Conversely, overexpression of caveolin-1 downregulates PAI-1 both at
the mRNA and protein level (71±11% and 499±189% decrease of PAI-1
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Fig. 3A, B).
The second set of genes modulated by caveolin-1 includes genes
involved in the regulation of cell adhesion (10%, ITGA1, ITGA2, ITGA3,
ITGA4, ITGA5, ITGAV, ITGB1, ITGB3 and ITGB5, Fig. 2F). The later classwas
interesting not only because it represented half of the genes affected by
caveolin-1, but because their expression was inversely correlated with
caveolin-1. Therefore, caveolin-1 might control the function of the
collagen receptor α2β1, the laminin receptor α3β1 and the ﬁbronectin
receptors α5β1 and αvβ3/5. Although modulation of caveolin-1 sig-
niﬁcantly affected α1 at the mRNA level (25±13% decrease of α1 mRNA
in pEGFPcav-1 versus pEGFPcontrol and 32±23% increase of α1 mRNA in
siRNAcav-1 versus siRNAcontrol, Fig. 2F), the protein could not be detected.
α4 and β3 were not signiﬁcantly altered at the mRNA level. Although
modulation of caveolin-1 signiﬁcantly affected α3 and αv at the mRNA
level (39±12% and 20±14% decrease ofα3 andαv mRNA respectively in
pEGFPcav-1 versus pEGFPcontrol and 67±28% and 37±11% increase of α3
and αv mRNA respectively in siRNAcav-1 versus siRNAcontrol, Fig. 2F),
down-regulation of caveolin-1 had no effect onα3/V protein levelswhile
caveolin-1 up-regulation decreased α3/V protein levels (41±5% and
26±7% decrease of α3 and αv protein respectively in pEGFPcav-1 versus
pEGFPcontrol, Supplementary data).
However, down-regulation of caveolin-1 up regulates α2, α5 and
β1 both at the mRNA and protein level (231±23%, 35±7% and 61±6%
increase ofα2,α5 and β1 mRNA respectively and 83±16%, 50±10% and
80±20% increase of α2, α5 and β1 protein respectively in siRNAcav-1
versus siRNAcontrol, Fig. 4A, B and Supplementary data). Conversely,
overexpression of caveolin-1 downregulates α2, α5 and β1 both at the
mRNA and protein level (56±9% and 31±4% decrease of α5 and β1
mRNA respectively and 39±4%, 50±17% and 62±9% decrease of α2, α5
and β1 protein respectively in pEGFPcav-1 versus pEGFPcontrol, Fig. 4A, B
and Supplementary data). Similar data were obtained in another
glioma cell line, A172 (Fig. 4C). By ﬂow cytometry, we showed that
downregulation of caveolin-1 increases α5β1 integrin surface expres-
sion (25±5% and 44±14% increase of α5 and β1 respectively in
siRNAcav-1 versus siRNAcontrol, Fig. 4D). Conversely, overexpression of
caveolin-1 reduces the levels of α5β1 integrin exposed at the cell
surface (57±10% and 14±2% reduction of α5 and β1 respectively in
pEGFPcav-1 versus pEGFPcontrol, Fig. 4D). Altogether, data suggest that
α2, α5 and β1 integrin subunit expression is inversely correlated to
caveolin-1.
We hypothesized that modulation of caveolin-1 would affect cell
adhesion to extracellular matrix components as ﬁbronectin and
collagen. Inhibition of caveolin-1 increased the attachment to
ﬁbronectin (24% increase in siRNAcav-1 versus siRNAcontrol, Fig. 4E).
Conversely, up-regulation of caveolin-1 reduced cell adhesion to
ﬁbronectin (20% decrease in pEGFPcav-1 versus pEGFPcontrol, Fig. 4E).
No alteration of adhesiveness to collagen was observed under the
conditions tested. A series of blocking experiments were undertaken
to determine if α5β1 integrins were involved in the regulation of cell
adhesiveness observed after caveolin-1 manipulation. As the α2
integrin subunit was shown to be the only other integrin
which expression was inversely correlated to caveolin-1, we down-
regulated α2 and α5 integrin subunits in cells depleted in caveolin-1
(shRNAcav-1-transfected U87MG in which α2β1 and α5β1 are up-
regulated). Although the enhanced attachment of cells to ﬁbronectin
was not affected by the removal of the α2 integrin subunit (19±4%
increase in shRNAcav-1/siRNAcontrol and 12±5% increase shRNAcav-1/
siRNAα2 versus shRNAcontrol/siRNAcontrol, Fig. 4F left panel), it was
totally abolished by the removal of the α5 integrin subunit (19±4%
increase in shRNAcav-1/siRNAcontrol and 3±1% increase shRNAcav-1/
siRNAα5 versus shRNAcontrol/siRNAcontrol, Fig. 4F right panel). Again, no
alteration of adhesiveness to collagen was observed under the
conditions tested. Data suggest for the ﬁrst time that caveolin-1
controls the expression of a functional α5β1 integrin in glioblastoma
with a consequence on the adhesive phenotype of cells.3.3. Involvement of α5β1 integrins in the phenotypic modulation induced
by caveolin-1
As biological effects (proliferation, clonogenicity and transmigra-
tion) observed following modulation of caveolin-1 might occur
independently of α5β1 integrin, we generated U87MG expressing
various levels of the α5 subunit and compared their phenotype to
that of cells expressing various levels of caveolin-1. Depletion (in
shRNAα5- versus shRNAcontrol-transfected cells) and overexpression
(in pcDNAα5- versus pcDNAcontrol-transfected cells) ofα5 was detected
at the mRNA and protein levels (Figs. 5A–B). We chose the pcDNAα5 E7
clone that expressed α5 levels close to those observed in siRNAcav-1-
transfected cells and the pcDNAα5 F8 clone that expressed higher
levels of α5 (Fig. 5A, B). No modulation of β1 or caveolin-1 was
observed in any of these cell lines at the protein level, although
caveolin-1 mRNA appears signiﬁcantly increased in cells overexpres-
sing the α5 subunit (Fig. 5A).
Upregulation of α5 increases proliferation similarly to that
observed in caveolin-1-depleted cells (32±18% and 52±16% increase
in pcDNAα5 E7 and pcDNAα5 F8 versus pcDNAcontrol respectively,
53±19% increase in siRNAcav-1 versus siRNAcontrol, Fig. 5C). Down-
regulation of α5 decreases proliferation similarly to that observed in
caveolin-1-overexpressing cells (39±11% decrease in shRNAα5 D4
versus shRNAcontrol, 47±8% decrease in pEGFPcav-1 versus pEGFPcontrol,
Fig. 5C). Upregulation of α5 increases clonogenicity similarly to that
observed in caveolin-1-depleted cells (85±30% and 80±24% increase
in pcDNAα5 E7 and pcDNAα5 F8 versus pcDNAcontrol respectively,
66±8% increase in siRNAcav-1 versus siRNAcontrol, Fig. 5D). Down-
regulation of α5 decreases clonogenicity similarly to that observed
in caveolin-1-overexpressing cells (35±5% decrease in shRNAα5-D4
versus shRNAcontrol, 42±8% decrease in pEGFPcav-1 versus pEGFPcontrol,
Fig. 5D).
We down-regulated α2 and α5 integrin subunits in cells depleted
in caveolin-1 (shRNAcav-1-transfected U87MG inwhich α2β1 and α5β1
are up-regulated). The enhanced clonogenicity of cells was not
affected by the removal of the α2 integrin subunit (46±5% increase
in shRNAcav-1/siRNAcontrol and 38±10% increase shRNAcav-1/siRNAα2
versus shRNAcontrol/siRNAcontrol, Fig. 5E left), but it was totally
abolished by the removal of the α5 integrin subunit (46±5% increase
in shRNAcav-1/siRNAcontrol and 2±5% increase shRNAcav-1/siRNAα5
versus shRNAcontrol/siRNAcontrol, Fig. 5E right).
Altogether, results suggest that the effects of caveolin-1 on
proliferation and clonogenicity of glioblastoma cells were mediated
by α5β1 integrins.
3.4. Caveolin-1 affects the effect of SJ749 on clonogenicity
and transmigration
We next investigated the consequences of altered caveolin-1 levels
on the sensitivity to a non peptidic α5β1 integrin antagonist SJ749.
SJ749 dose-dependently reduces the surviving fraction of all cell lines
(Fig. 6A). However, SJ749 was more efﬁcient in caveolin-1-depleted
cells (45±7% versus 75±7% inhibition at 10 μM and 80±6% versus
96±3% inhibition at 30 μM in siRNAcontrol and siRNAcav-1 respec-
tively, Fig. 6A). Conversely, over-expression of caveolin-1 reduces the
effect of SJ749 (39±11% versus 37±13% inhibition at 10 μM and 93±1%
versus 78±9% inhibition at 30 μM in pEGFPcontrol and pEGFPcav-1
respectively, Fig. 6A).
As glioblastoma are aggressively invasive tumors, the ability of
cells to transmigrate in the presence of SJ749 was determined. SJ749
signiﬁcantly reduces the invasion of all cell lines (Fig. 6B). However,
SJ749 was more efﬁcient in caveolin-1-depleted cells (75±4% versus
97±0% inhibition at 10 μM in siRNAcontrol and siRNAcav-1, Fig. 6B).
Conversely, over-expression of caveolin-1 reduces the effect of SJ749
(56±2% versus 44±7% inhibition at 10 μM in pEGFPcontrol and
pEGFPcav-1 respectively, Fig. 6B). Thus, data suggest that SJ749 might
360 S. Martin et al. / Biochimica et Biophysica Acta 1793 (2009) 354–367be even more efﬁcient in tumors expressing high levels of α5β1
integrin and low levels of caveolin-1.
3.5. Caveolin-1 regulates α5β1 integrins through the MAP
kinase pathway
Finally, we analyzed how caveolin-1 might affect α5β1 integrin
expression starting with pathways known to be involved in caveolin-1
signaling and in α5β1 integrin regulation, like the mitogen activated
protein kinases pathway. Down-regulation of caveolin-1 induced the
phosphorylation of p44/42-MAPK, whereas total levels of p44/42-
MAPK were unchanged (ratio [phospho-p44/42-MAPK]/[p44/42-
MAPK] increases from 0.7±0.1 to 1.1±0.1% between siRNAcontrol andFig. 4. Caveolin-1 regulatesα5β1 integrin expression. (A) ITGA2, ITGA5 and ITGB1mRNA (α2,α
siRNAcav-1 (100 nM for 72 h) or stablywith pEGFPcontrol or pEGFPcav-1. Histograms represent th
pEGFPcav-1-transfected cells versus respective control (i.e. siRNAcontrol and pEGFPcontrol) norma
GFP-tagged cav-1) and GAPDH was determined by western blot (WB) in U87MG transfected t
pEGFPcav-1. Western blots are representative of 3–5 independent experiments. Histograms sh
densitometry analysis in siRNAcav-1- and pEGFPcav-1-transfected cells versus respective cont
caveolin-1 (cav-1 or GFP-tagged cav-1) andGAPDHwas determined bywestern blot (WB) in A
pEGFPcontrol or pEGFPcav-1. Western blots are representative of 3–5 independent experiments
transfected transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pEGFP
and IgG-PE for EGFP-transfected cells. Histograms show the percentage of α5 and β1 express
(i.e. siRNAcontrol and pEGFPcontrol) normalized with IgG control. (E) Adhesion of U87MG tr
pEGFPcontrol or pEGFPcav-1 was determined using the adhesion assay on poly-L-lysine (PL, 10
percentage of adhesion of siRNAcav-1- and pEGFPcav-1-transfected cells versus respective cont
representing themaximum cell adhesion used for normalization. Data are represented asmea
shRNAcav-1-stably transfectedU87MG transiently co-transfectedwith siRNAcontrol, siRNAα2 or
100 μg/ml) and ﬁbronectin (FN,10 μg/ml). Western blot show the levels of theα2 andα5 integ
on FN with the non speciﬁc adhesion on PL representing the maximum cell adhesion used fsiRNAcav-1, Fig. 7A). Conversely, overexpression of caveolin-1 reduces
the phosphorylation of p44/42-MAPK, whereas total levels of p44/42-
MAPK were unchanged (ratio [phospho-p44/42-MAPK]/[p44/42-
MAPK] drops from 0.9±0.1 to 0.6±0.1% between pEGFPcontrol and
pEGFPcav-1, Fig. 7A). In contrast, phosphorylation of p38-MAPK or JNK/
SAPK-MAPK was not induced under the condition tested (Fig. 7A). To
evaluate the role of p44/42-MAPK in α5β1 integrin induction, cells
were treated with the MAPK kinase inhibitor U0126. The induction of
both the α5 and the β1 integrin subunit observed after down-
regulation of caveolin-1 was abolished by U0126 (Fig. 7B). Similar
results were observed for the α2 integrin subunit (not shown). No
modulations of the FAK- and β-catenin-dependent signaling pathway
were observed in our study (not shown). Thus, data suggest that the5 andβ1)was determined by qPCR in U87MG transfected transientlywith siRNAcontrol or
e percentage of increase or decrease of ITGA2, ITGA5 and ITGB1mRNA in siRNAcav-1- and
lizedwith the reporter gene, cyclophilin. (B) Expression ofα2,α5,β1, caveolin-1 (cav-1 or
ransiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pEGFPcontrol or
ow the percentage ofα2,α5, β1 and caveolin-1 (cav-1) protein expression determined by
rol (i.e. siRNAcontrol and pEGFPcontrol) normalized with GAPDH. (C) Expression of α5, β1,
172 transfected transientlywith siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stablywith
. (D) Cell surface expression of α5 and β1 was determined by ﬂow cytometry in U87MG
control or pEGFPcav-1. Secondary antibodies were IgG-Alexa488 for siRNA-transfected cells
ion determined in siRNAcav-1- and pEGFPcav-1-transfected cells versus respective control
ansfected transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with
0 μg/ml), ﬁbronectin (FN, 10 μg/ml) and collagen (COL, 10 μg/ml). Histograms show the
rol (i.e. siRNAcontrol and pEGFPcontrol) on FN and COLwith the non speciﬁc adhesion on PL
n (n=3–5)±SEM (⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001). (F) Adhesion of shRNAcontrol- and
siRNAα5 (100 nM for 72 h)was determined using the adhesion assay on poly-L-lysine (PL,
rin subunit and GAPDH in each conditions. Histograms show the percentage of adhesion
or normalization. Data are represented as mean (n=4–6)±SEM (nsPN0.05, ⁎Pb0.05).
Fig. 4 (continued).
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362 S. Martin et al. / Biochimica et Biophysica Acta 1793 (2009) 354–367p44/42-MAPK pathway plays a crucial role in the regulation of α5β1
integrin by caveolin-1.
4. Discussion
Despite several studies showing that caveolin-1 expression is
increased but variably displayed in astroglial-derived tumors (http://
cgap.nci.nih.gov) [12–17], the biological signiﬁcance of caveolin-1 inglioblastoma remains unknown. Our study showed that modulation of
caveolin-1 expression in U87MG greatly modiﬁes the pattern of
growth, clonogenicity and transmigration. The reduction of caveolin-1
expression renders U87MG more proliferative, invasive and increased
their clonogenic capacity. Conversely, increased expression of caveo-
lin-1 slowed down proliferation, clonogenicity and transmigration of
U87MG. Thus caveolin-1 expression seems correlated to glioma
aggressiveness. Importantly, data highlight care that must be taken
Fig. 5. Involvement of α5β1 integrin in the phenotypic modulation induced by caveolin-1. (A) ITGA5, ITGB1 and CAV1 (α5, β1, caveolin-1) mRNAwas determined by qPCR in U87MG
transfected transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pcDNAcontrol or pcDNAα5 (clones E7 and F8), pEGFPcontrol or pEGFPcav-1, shRNAcontrol or
shRNAα5 (clone D4). Histograms represent the percentage of increase or decrease of ITGA5, ITGB1 and CAV1 mRNA in siRNAcav-1, pcDNAα5E7-, pcDNAα5F8-, EGFPcav-1- and
shRNAα5D4-transfected cells versus respective control (i.e. siRNAcontrol, pcDNAcontrol, pEGFPcontrol and shRNAcontrol) normalized with the reporter gene, cyclophilin. (B) Expression of
α5, β1, caveolin-1 (cav-1) and GAPDH was determined by western blot (WB) in U87MG transfected stably with pcDNAcontrol, pcDNAα5 (clones E7 and F8), shRNAcontrol or shRNAα5
(clone D4). Western blots are representative of 3–5 independent experiments. Histograms show the percentage of α5, β1 and caveolin-1 (cav-1) protein expression determined by
densitometry analysis in siRNAcav-1-, pcDNAα5E7-, pcDNAα5F8-, EGFPcav-1- and shRNAα5D4-transfected cells versus respective control (i.e. siRNAcontrol, pcDNAcontrol, pEGFPcontrol and
shRNAcontrol) normalized with GAPDH. (C) Proliferation of U87MG transfected transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pcDNAcontrol or pcDNAα5
(clones E7 and F8), pEGFPcontrol or pEGFPcav-1, shRNAcontrol or shRNAα5 (clone D4) was determined at 72 h using the MTS assay. Histograms represent the percentage of proliferation
of siRNAcav-1-, pcDNAα5E7-, pcDNAα5F8-, EGFPcav-1- and shRNAα5D4-transfected cells versus respective control (i.e. siRNAcontrol, pcDNAcontrol, pEGFPcontrol and shRNAcontrol). (D)
Clonogenicity of U87MG transfected transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pcDNAcontrol or pcDNAα5 (clones E7 and F8), pEGFPcontrol or
pEGFPcav-1, shRNAcontrol or shRNAα5 (clone D4) was determined using the clonogenic assay. Histograms represent the percentage of residual clones formed by siRNAcav-1-,
pcDNAα5E7-, pcDNAα5F8-, EGFPcav-1- and shRNAα5D4-transfected cells versus respective control (i.e. siRNAcontrol, pcDNAcontrol, pEGFPcontrol and shRNAcontrol) after 72 h growth in 2%-
FCS medium and 6 days regrowth. Data are represented as mean (n=3–5)±SEM (⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001). (E) Clonogenicity of shRNAcontrol- and shRNAcav-1-stably
transfected U87MG transiently co-transfected with siRNAcontrol, siRNAα2 or siRNAα5 (100 nM for 72 h) was determined using the clonogenic assay. Histograms represent the
percentage of residual clones formed by shRNAcav-1/siRNAcontrol shRNAcontrol/siRNAα2-, shRNAcontrol/siRNAα5-, shRNAcav-1/siRNAα2- and shRNAcav-1/siRNAα5-transfected cells versus
shRNAcontrol/siRNAcontrol after 72 h growth in 2%-FCS medium and 6 days regrowth. Data are represented as mean (n=7)±SEM (nsPN0.05, ⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001).
Plating efﬁciency is 0.4±0.1, 0.6±0.1, 0.5±0.1, 0.6±0.1, 0.5±0.1 and 0.4±0.1 for shRNAcontrol/siRNAcontrol, shRNAcav-1/siRNAcontrol, shRNAcontrol/siRNAα2, shRNAcav-1/siRNAα2,
shRNAcontrol/siRNAα5 and shRNAcav-1/siRNAα5 respectively.
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as radiation or some chemotherapeutic agents. Induction of caveolin-1
in tumor cells and tumor endothelial cells following radiation
is responsible for the acquisition of a radio-resistance phenotype
[19,20]. Conversely, HDAC inhibitors, proteasome inhibitors or
VEGF receptor inhibitors, which are in clinical trials for glioblastoma
(http://ClinicalTrials.gov) were shown to reduce caveolin-1 levels and
in light of our results might increase glioblastoma aggressivity.
Radiation- or chemotherapy-induced dysregulation of caveolin-1
might therefore critically affect glioblastoma aggressiveness but also
responsiveness to such treatments and partially explain how such
tumors become refractory to treatment. Therefore, identifying more
carefully caveolin-1 signaling pathways in glioblastoma might lead to
identify more active compounds.Getting further insight into cancer genes/pathways altered by
caveolin-1 manipulation, we showed that only 20% of the genes
probed were affected. Six percent of them were involved in the
regulation of invasive processes amongwhich the proteinase inhibitor
PAI-1. Increased PAI-1 expression was reported in highly invasive
high-grade glioma [21]. In accordance, increased secretion of PAI-1
was observed in caveolin-1-depleted U87MG that exerted enhanced
invasivity. In contrast, forced expression of caveolin-1 reduced both
signiﬁcantly the invasive capacity of cells and the secretion of PAI-1.
Although the precise role of PAI-1 needs to be clariﬁed, it has recently
been proposed that elevated levels of PAI-1 promote cancer cell
detachment and tumor dissemination by causing internalization of
PAI-1/uPA/uPAR/integrin complex [22,23]. Interestingly, the main
genes affected by caveolin-1 (10%) belonged to the integrin family.
Fig. 6. Caveolin-1 affects the effect of SJ749 on clonogenicity and transmigration. (A) Clonogenicity of U87MG transfected transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h)
or stably with pEGFPcontrol or pEGFPcav-1 was determined after 72 h treatment with solvent (H2O/Methanol) or indicated concentration of SJ749 and 6 days regrowth using the
clonogenic assay. Histograms represent the surviving fraction of siRNAcav-1- and EGFPcav-1-transfected cells versus respective control (i.e. siRNAcontrol and pEGFPcontrol) in the presence
of the solvent or SJ749. Plating efﬁciency is 0.5±0.2, 0.8±0.3, 0.5±0.1 and 0.3±0.1 for siRNAcontrol, siRNAcav-1, pEGFPcontrol and pEGFPcav-1 respectively. (B) Transmigration of U87MG
transfected transiently with siRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pEGFPcontrol or pEGFPcav-1 was determined in the presence of solvent (H2O/Methanol) or 10 μM
SJ749 using ﬁbronectin (FN)-coated transwell. Histograms represent the percentage of siRNAcav-1- and EGFPcav-1-transfected cells which transmigrated through ﬁbronectin (FN)
versus respective control (i.e. siRNAcontrol and pEGFPcontrol) after 24 h in the presence of the solvent or SJ749. Data are represented as mean (n=3–5)±SEM (⁎Pb0.05, ⁎⁎Pb0.01 and
⁎⁎⁎Pb0.001). Representative pictures of 3 independent experiments.
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of integrins was always inversely correlated to caveolin-1. Data
suggested therefore a regulation of integrins by caveolin-1 at the
transcription level. Integrins represent an important class of hetero-
dimeric cell-adhesion receptors that are involved in various processes
deregulated in many pathologies especially in cancer. Although
caveolin-1 is crucial for integrin signaling and dynamic, the mecha-nism by which it exerts its control is far from being elucidated.
Historically, caveolin-1 was identiﬁed as an adaptor that physically or
functionally linked α1 and α5 to growth signaling pathway through
Fyn/Shc [24,25] or β1 to adhesion/migration signaling pathways
through src/FAK [26] and as a regulator of integrin trafﬁcking/
internalization [27–29]. However, none of these studies ever men-
tioned the ability of caveolin-1 to control integrin expression at the
Fig. 7. Caveolin-1 regulates α5β1 integrins through the MAP kinase pathway. (A) Expression of phospho-SAPK/JNK, SAPK/JNK, phospho-p44/42-MAPK, p44/42-MAPK, phospho-p38-
MAPK, p38-MAPK and GAPDHwas determined bywestern blot (WB) in U87MG transfected transiently with shRNAcontrol or siRNAcav-1 (100 nM for 72 h) or stably with pEGFPcontrol or
pEGFPcav-1. Histograms represent the ratio (phospho-p44/42-MAPK)/(p44/42-MAPK) in shRNAcontrol-, siRNAcav-1-, pEGFPcontrol- and pEGFPcav-1-transfected U87MG. Data are
represented as mean (n=3–5)±SEM (⁎Pb0.05 and ⁎⁎Pb0.01). (B) Expression of α5, β1, phospho-p44/42-MAPK, p44/42-MAPK and GAPDH was determined by western blot (WB) in
U87MG transfected transiently with shRNAcontrol or siRNAcav-1 (100 nM for 72 h) treated either with solvent (DMSO) or U0126 (10 μM) for 24 h. Histograms show the percentage ofα5
and β1 integrin subunit protein expression determined by densitometry analysis normalized to GAPDH. Data are represented as mean (n=4)±SEM (⁎Pb0.05, ⁎⁎Pb0.01).
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recently as a potential antitumor target [14,30–33]. Gain- and loss-
of-function showed that the reverse correlation between caveolin-1
and α5β1 integrins was observed both at the mRNA and protein level
in at least two different types of glioma cells and in a colon
carcinoma cell line (not shown), with high levels of α5β1 integrins
in caveolin-1-depleted cells and low levels of α5β1 integrins in
caveolin-1-overexpressing cells. Although an alteration of caveolin-
1-mediated integrin internalization processes affecting the levels of
integrin present at the cell surface that might involve PAI-1 cannot be
ruled out, caveolin-1 inﬂuences α5β1 integrin gene expression.
Accordingly, caveolin-1 was only recently shown as an indirect
regulator of genes involved in tumorigenesis, like cyclin D1 and
survivin through the β-catenin-Tcf/Lef pathway [7,8,34,35] and the IGF
receptor and BRCA1 through Sp1- and p53-dependent pathway [4,5]
or as a direct regulator through its binding to promoter elements of
growth-associated genes after relocation of caveolin-1 into the
nucleus [36]. As no relocation of β-catenin into the nucleus and no
alteration either in the expression or in the activity of p53 could
be observed in our study, the involvement of β-catenin- and p53-
dependent pathway seems unlikely (data not shown). α5β1 integrins
were also recently shown to be negatively regulated by E-cadherin
through the EGFR/FAK/p44/42-MAPK-dependent signaling pathway
[33]. Although FAK seems not involved in the regulation of α5β1
integrin expression as neither its expression nor its phosphorylation
status was altered by caveolin-1 (data not shown), p44/42-MAPK
seems to play a crucial role. We reported here that loss of caveolin-1
was associated with hyperphosphorylation of p44/42-MAPK.When blocked using the MAPK kinase inhibitor U0126, the induction
of α5β1 integrin associated with caveolin-1 depletion was abolished.
Caveolin-1 is well known to interact with p44/42-MAPK through the
CSD (caveolin scaffolding domain) and to inhibit its activity.
Consistent with this action, caveolin-1 KO mice show increased
activation of p44/42-MAPK [37,38]. Therefore we suggest that loss of
caveolin-1 frees p44/42-MAPK from repression allowing induction of
α5β1 integrin but also probably other genes such as the α2 integrin
subunit. Further studies will be needed to decipher the molecular
pathway involved in the regulation of α5β1 integrin by caveolin-1/
p44/42-MAPK.
The phenotypic alteration observed after caveolin-1 modulation
can be linked to caveolins themselves and the diverse array of
molecules with which it was reported to interact. Our study showed
that the major class of genes modulated by caveolin-1 is the integrin
subfamily. Data suggest that the functionally relevant integrin
regulated by caveolin-1 is the ﬁbronectin receptor α5β1. This was
supported by blocking studies showing that increased adhesion and
clonogenicity observed following caveolin-1 down-regulation
remained unaffected by the removal of the α2 integrin subunit but
was totally abolished by the removal of the α5 integrin subunit.
Moreover, the consequences of caveolin-1 modulation on prolifera-
tion and clonogenicity could be reproduced by manipulation of α5β1
integrins. Even subtle up- or down-regulations of α5 integrin
subunits as those induced by caveolin-1 were sufﬁcient to carry out
the signals initiated by caveolin-1 as no additional effects could be
observed by forcing or abrogating further α5 expression. Similarly, a
discrete modulation of α5 mRNA and protein levels induced by
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cells [39]. We previously reported that SJ749, the most selective
nonpeptidic α5β1 integrin antagonist described so far [32,40,41],
inhibits cell proliferation and anchorage-independent growth of A172
and U87MG without inducing apoptosis [42,43]. The level of α5β1
integrin seemed critical in the antagonistic effects of the drug [42,43].
In accordance, although SJ749 signiﬁcantly reduced clonogenic
survival and transmigration of U87MG, it was more efﬁcient in
highly proliferative and invasive cells (expressing high levels of α5β1
integrin and low levels of caveolin-1). Altogether data suggest that
the phenotypic changes (growth, adhesion and transmigration)
resulting from caveolin-1 modulation are indeed mediated by α5β1
integrin. This is also supported by some preliminary studies showing
that genes altered by caveolin-1 (identiﬁed by PCR array) are
modiﬁed to the same extent after α5β1 integrin modulation. More
importantly, our study is supportive to publications highlighting the
potential role of α5β1 integrins as therapeutic targets in several
cancers [33,42,44,45].
In conclusion, caveolin-1 regulates growth, clonogenicity and
transmigration of glioblastoma cells. Among the genes targeted by
caveolin-1, we identiﬁed α5β1 integrin as the principal mediator of
caveolin-1 effects. The status of caveolin-1/α5β1 integrin might be a
usefulmarker of the tumor behaviorwith caveolin-1low/α5β1high levels
that would indicate that the tumor is highly proliferative and
inﬁltrative but highly responsive toα5β1 integrin antagonists, whereas
caveolin-1high/α5β1low levels could indicate a delay in tumor progres-
sion and reduced response to the drug. Our data open new aspects in
the understanding of the caveolin-1/α5β1 integrin partnership in
fundamental cell biology and its contribution to glioma biology.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbamcr.2008.09.019.
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